 JanOne Inc. NASDAQ: JAN, a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, has executed a manufacturing agreement for the formulation and manufacturing of TV1001SR, a treatment for Peripheral Artery Disease PAD. PAD affects over 8.5 million people in the United States and there are currently no direct treatments for PAD on the market today. Research Market Future MRFR values the PAD market at 3.47 billion in the United States by 2023.1 